
NYSEHealthcareMedical - Diagnostics & Research
最新資料
US$155.95
+US$1.77 · +1.15%
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
一般交易時段
US$155.95
+US$1.77 · +1.15%
盤中時間採用ET。市場資料可能有所延遲。
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
日內區間
目前US$155.95
52週區間
目前US$155.95
盤中時間採用ET。市場資料可能有所延遲。
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
日內區間
目前US$155.95
52週區間
目前US$155.95
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 28.56億 USD | 27.55億 USD | 27.51億 USD | 33.12億 USD | 38.28億 USD |
| 銷貨成本 | 13.4億 USD | 14.32億 USD | 14.28億 USD | 15.51億 USD | 15.46億 USD |
| 毛利 | 15.16億 USD | 13.23億 USD | 13.22億 USD | 17.61億 USD | 22.82億 USD |
| 研究與開發 | 2.16億 USD | 1.97億 USD | 2.17億 USD | 2.22億 USD | 2億 USD |
| 銷售、一般及管理費用 | 9.45億 USD | 7.15億 USD | 7.06億 USD | 7.58億 USD | 7.42億 USD |
| 營業費用 | 11.59億 USD | 9.12億 USD | 9.23億 USD | 9.8億 USD | 9.42億 USD |
| 利息收入 | 3110.3萬 USD | 7319萬 USD | 7213.1萬 USD | 358.9萬 USD | 224.1萬 USD |
| 利息支出 | 9218.5萬 USD | 9627.8萬 USD | 9881.3萬 USD | 1.04億 USD | 1.02億 USD |
| 折舊和攤銷 | 4.05億 USD | 4.28億 USD | 4.32億 USD | 4.27億 USD | 3.11億 USD |
| 營業利益 | 3.57億 USD | 4.11億 USD | 3.99億 USD | 7.81億 USD | 13.4億 USD |
| 淨利 | 2.42億 USD | 2.96億 USD | −1.18億 USD | 5.69億 USD | 9.43億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$132.13
下跌空間 15.27%年度分割調整後的每股現金分配。
US$0.28
2025年(完整年度)0.0% 自從 2021
2026年(部分年度):US$0.21
US$0.28
2,021
US$0.28
2,022
US$0.28
2,023
US$0.28
2,024
US$0.28
2,025
US$0.21
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息即將實施 | 2026年10月23日 | US$0.07Quarterly | 2026年10月23日 | 2026年11月13日 |
股息 | 2026年7月17日 | US$0.07Quarterly | 2026年7月17日 | 2026年8月7日 |
股息 | 2026年4月17日 | US$0.07Quarterly | 2026年4月17日 | 2026年5月8日 |
股息 | 2026年1月16日 | US$0.07Quarterly | 2026年1月16日 | 2026年2月6日 |
股息 | 2025年10月17日 | US$0.07Quarterly | 2025年10月17日 | 2025年11月7日 |
股息 | 2025年7月18日 | US$0.07Quarterly | 2025年7月18日 | 2025年8月8日 |
除息 2026年10月23日
US$0.07
Quarterly
2026年10月23日登記 · 支付日 2026年11月13日
除息 2026年7月17日
US$0.07
Quarterly
2026年7月17日登記 · 支付日 2026年8月7日
除息 2026年4月17日
US$0.07
Quarterly
2026年4月17日登記 · 支付日 2026年5月8日
除息 2026年1月16日
US$0.07
Quarterly
2026年1月16日登記 · 支付日 2026年2月6日
除息 2025年10月17日
US$0.07
Quarterly
2025年10月17日登記 · 支付日 2025年11月7日
除息 2025年7月18日
US$0.07
Quarterly
2025年7月18日登記 · 支付日 2025年8月8日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T332.18億0.03%129.43兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI4.56億0.02%2.3兆 USD0.03%US$381.41-0.14%
Vanguard S&P 500 ETFVOO3.81億0.02%1.8兆 USD0.03%US$714.95-0.09%
Vanguard Morningstar Small-Cap ETFVB3.3億0.18%1853億 USD0.03%US$288.11-0.47%
iShares Core S&P 500 ETFIVV2.29億0.03%8964.4億 USD0.03%US$781.27-0.09%
Vanguard Morningstar Small-Cap Value ETFVBR2.1億0.31%682億 USD0.05%US$234.61+0.08%
State Street SPDR S&P 500 ETFSPY2.09億0.03%8172億 USD0.09%US$777.8-0.10%
Dimensional - US Targeted Value ETFDFAT1.48億0.49%301.22億 USD0.33%US$67.515+0.36%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
iShares Core S&P 500 ETFIVV
Vanguard Morningstar Small-Cap Value ETFVBR
State Street SPDR S&P 500 ETFSPY
Dimensional - US Targeted Value ETFDFATAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。